|
|
Predicting HIV care costs using CD4 counts from clinical trials.(TRENDS FROM THE FIELD)
- Article from:
-
American Journal of Managed Care
- Article date:
-
September 1, 2007
- Author:
- Hill, Andrew; Gebo, Kelly
|
Copyright informationCOPYRIGHT 2007 Ascend Media. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Objective: To predict the effects of a new antiretroviral agent on the costs of care in a US HIV care setting.
Methods: Recent data on costs of patient care by CD4 count from 2 US cohorts (the HIV Research Network cohort and patients receiving primary care at the University of Alabama at Birmingham HIV clinic) were combined with CD4 count data from the POWER trials of the protease inhibitor darunavir. Patients in the POWER trials received either darunavir plus low-dose ritonavir (darunavir/r) or selected control protease inhibitors. The effects of rising CD4 counts with darunavir/r 600/100 mg twice daily on healthcare costs were predicted by using the US cohort data and ...
<50, 50-200, 200-500 and><50, 50-200, 200-350 and>